Celcuity Inc. (CELC)
Celcuity Inc. (CELC)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -52,841 | -50,973 | -43,804 | -82,265 |
| Depreciation | 47 | 49 | 41 | 77 |
| Stock-based compensation | 5,325 | 9,456 | 6,779 | 5,148 |
| Amortization of debt issuance costs and discount | 1,252 | 1,271 | 778 | 1,088 |
| Payment-in-kind interest | 325 | 331 | 272 | 501 |
| Non-cash interest income | 883 | NaN | NaN | NaN |
| Non-cash operating lease expense | -3 | -2 | -3 | -2 |
| Change in accrued interest income | NaN | -1,470 | 1,180 | -340 |
| Prepaid clinical trial costs | -3,522 | 12,127 | NaN | NaN |
| Other current assets | 976 | -7,709 | 5,449 | 5,251 |
| Accrued expenses | NaN | NaN | -2,195 | 6,459 |
| Accounts payable | 4,080 | -4,825 | -55 | 1,840 |
| Accrued clinical trial costs | -8,055 | 118 | NaN | NaN |
| Other accrued expenses | -6,858 | 15,388 | NaN | NaN |
| Net cash used in operating activities | -55,065 | -36,399 | -44,816 | -72,065 |
| Proceeds from maturities of investments | 50,000 | 103,462 | 32,307 | 196,738 |
| Purchases of investments | 15,196 | 0 | 289,821 | 106,521 |
| Purchases of property and equipment | 249 | 53 | 97 | 99 |
| Purchases of capitalized software | 36 | NaN | NaN | NaN |
| Net cash provided by investing activities | 34,519 | 103,409 | -257,611 | 90,118 |
| Proceeds from employee stock purchases | NaN | 458 | 0 | 253 |
| Proceeds from exercise of common stock options | 206 | 1,101 | 2,364 | 20 |
| Proceeds from exercise of common stock warrants | 31 | 23,591 | 12,870 | 5,600 |
| Proceeds from convertible debt, net of debt issuance costs of 6,246 and 0 during the years ended december 31, 2025 and 2024, respectively | NaN | -472 | 195,476 | NaN |
| Proceeds from note payable, net of debt issuance costs of 2,255 and 2,438 during the years ended december 31, 2025 and 2024, respectively | NaN | -7 | 27,752 | 0 |
| Payments for debt issuance costs | NaN | NaN | NaN | 40 |
| Proceeds from an atm offering, net of issuance costs | NaN | NaN | NaN | 0 |
| Proceeds from equity offering, net of underwriting discounts and offering costs | NaN | -231 | 91,823 | 0 |
| Payments for secondary registration statement costs | 203 | -1 | 0 | 47 |
| Net cash provided by financing activities | 34 | 24,441 | 330,325 | 5,786 |
| Net change in cash and cash equivalents | -20,512 | 91,451 | 27,898 | 23,839 |
| Beginning of period | 165,703 | -51,737 | 22,515 | NaN |
| End of period | 145,191 | 91,451 | 74,252 | NaN |